Perseus Proteomics Inc.

4882

JP3836800007

Pharmaceuticals

Delayed Japan Exchange Other stock markets 11:30:00 16/05/2024 am IST			5-day change	1st Jan Change
311 ^JPY	-6.04%		-8.93%	-50.49%

10/05	Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	CI
07/03	Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch)	CI

Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch)

March 07, 2024

On March 7, 2024, Perseus Proteomics Inc. closed the transaction.

Latest news about Perseus Proteomics Inc.

Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	10/05	CI
Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch)	07/03	CI
Perseus Proteomics Inc. announced that it expects to receive ¥1.566 million in funding	20/02	CI
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023	14/02	CI
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	02/02	CI
Perseus Proteomics Secures Japanese Patent for Blood Cancer Drug Candidate	27/12	MT
Perseus Proteomics Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	13/11	CI
Perseus Proteomics Successfully Enrolls Patients in Phase I Clinical Trial of Anti-TfR1 Antibody for Polycythemia Vera	23/23/23	MT
Perseus Proteomics Inc. Announces Completion of Patients Enrollment in Phase I Clinical Trial for Polycythemia Vera (PV)	20/23/20	CI
Perseus Proteomics Launches Sales of Three Antibodies	12/23/12	MT
Perseus Proteomics Inc. Announces Sales Launch of New Antibodies/Reagents	11/23/11	CI
Perseus Proteomics, Inc. Announces Provision of Antibody Research Support Service Through Single Cell Cloning Technology	27/23/27	CI
Perseus Proteomics Inc. Announces on Dosing of the First Patient in Phase I/II Clinical Trial for Aggressive NK-Cell Leukemia	22/23/22	CI
Perseus Proteomics, Inc. Announces MOU Agreement on Joint Research on Super-Neutralizing Antibody with University of Toyama and Toyama Prefecture	29/23/29	CI
Perseus Proteomics Inc. Reports Impairment Loss for the First Quarter of the Fiscal Year 2023	14/23/14	CI
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	14/23/14	CI
Perseus Proteomics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	14/23/14	CI
Perseus Proteomics Inc. Announces the Interim Report of Phase I Clinical Trial of PPMX-T003	29/23/29	CI
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	12/23/12	CI
Perseus Proteomics Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	12/23/12	CI
Perseus Proteomics Inc. Updates Financial Forecast for the Year 2022	25/23/25	CI
Perseus Proteomics Inc. Announces That PMDA Has Finished Investigation of the Clinical Trial Notification of the Phase I/II Investigator-Led Clinical Trial	27/23/27	CI
Perseus Proteomics Inc. Submits the Clinical Trial Notification of the Phase I/II Investigator-Led Clinical Trial Among Aggressive Nk-Cell Leukemia Patients Using In-Development Anti-Transferrin Receptor Antibody PPMX-T003 as A Therapeutic to the PMDA by Hiroshima University Hospital	15/23/15	CI
An unknown buyer agreed to acquire a 6.38% stake in Perseus Proteomics Inc. from Fujifilm Corporation.	02/23/02	CI
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2022	13/23/13	CI

Perseus Proteomics Inc is a Japan-based company principally engaged in the research, development, manufacture and sale of pharmaceuticals. The Company is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The Company is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Sector

Pharmaceuticals

Calendar

08/11/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
PERSEUS PROTEOMICS INC.	-50.49%	2.63Cr
CSL LIMITED	-0.07%	9.14TCr
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	4.11TCr
BIOGEN INC.	-9.06%	3.43TCr
UCB	+55.32%	2.53TCr
BIOMARIN PHARMACEUTICAL INC.	-16.61%	1.53TCr
INCYTE CORPORATION	-9.14%	1.28TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.11%	1.16TCr
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.61%	1.14TCr
SWEDISH ORPHAN BIOVITRUM AB	+7.79%	915.59Cr

Biopharmaceuticals